Get the Stockscreener App
302.00
2.38%
7.015
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Ligand Pharmaceuticals Inc stock is traded at $302.00, with a volume of 106.95K.
It is up +2.38% in the last 24 hours and up +9.03% over the past month.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
See More
Previous Close:
$294.99
Open:
$298.18
24h Volume:
106.95K
Relative Volume:
0.46
Market Cap:
$6.02B
Revenue:
$274.48M
Net Income/Loss:
$153.56M
P/E Ratio:
40.95
EPS:
7.3755
Net Cash Flow:
$114.06M
1W Performance:
+2.37%
1M Performance:
+9.03%
6M Performance:
+34.17%
1Y Performance:
+64.76%
1-Day Range:
$296.85
$304.60
1-Week Range:
$292.28
$311.86
52-Week Range:
$175.89
$326.63
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Name
Ligand Pharmaceuticals Inc
Sector
Industry
Phone
858-550-7500
Address
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
302.00 | 6.02B | 274.48M | 153.56M | 114.06M | 7.3755 |
VRTX
Vertex Pharmaceuticals Inc
|
509.74 | 129.20B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
238.40 | 95.18B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.26 | 82.49B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
849.01 | 53.39B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.37 | 42.01B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-25-26 | Initiated | Barclays | Overweight |
| Aug-14-26 | Initiated | Leerink Partners | Outperform |
| Jul-21-26 | Resumed | Citigroup | Buy |
| Mar-11-26 | Initiated | BofA Securities | Buy |
| Dec-09-25 | Initiated | Citigroup | Buy |
| Apr-10-25 | Initiated | Stifel | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Resumed | Stephens | Overweight |
| Feb-04-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-06-20 | Initiated | Barclays | Overweight |
| Mar-24-20 | Downgrade | Argus | Buy → Hold |
| Mar-10-20 | Initiated | Guggenheim | Neutral |
| Feb-06-20 | Initiated | The Benchmark Company | Buy |
| Sep-19-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-03-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-06-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Oct-02-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-18 | Reiterated | Argus | Buy |
| Aug-17-18 | Initiated | Goldman | Neutral |
| Aug-08-18 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-21-18 | Initiated | Argus | Buy |
| Dec-27-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-17 | Resumed | H.C. Wainwright | Buy |
| Oct-05-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-16 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-11-16 | Initiated | Sidoti | Buy |
| Mar-03-16 | Initiated | H.C. Wainwright | Buy |
View All
Ligand Pharmaceuticals Inc Stock (LGND) Latest News
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo! Finance Canada
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo! Finance Canada
Ligand Pharma CLO Andrew Reardon sells $1.52 million in stock By Investing.com - Investing.com South Africa
Ligand Pharma CLO Andrew Reardon sells $1.52 million in stock - Investing.com
Form 4 Ligand Pharmaceuticals Incorporated For: 11 October By Investing.com - Investing.com Canada
Ligand Pharmaceuticals Incorpor (LGND) Stock forecasts - Yahoo Finance UK
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo Finance
Full Transcript: Ligand Pharmaceuticals Q2 2026 Earnings Call - Benzinga
Full Transcript: Ligand Pharmaceuticals Q2 2026 Earnings Call - Benzinga
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo! Finance Canada
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo Finance
Ligand Pharmaceuticals (LGND) Stock May Be 27% Undervalued After A New Royalty Deal - Yahoo Finance
Is Ligand Pharmaceuticals (LGND) Below Fair Value As It Funds AvenCell? - Yahoo Finance
Is Ligand Pharmaceuticals (LGND) Using AvenCell CAR-T Royalties To Redefine Its Cash-Flow Playbook? - Yahoo Finance
Form 4 Ligand Pharmaceuticals Incorporated For: 28 September By Investing.com - Investing.com Nigeria
Ligand (LGND)-AvenCell Deal: Most of the Funding Is Tied to Milestones - Yahoo Finance
Barclays Initiates Outperform on Ligand Pharmaceuticals (LGND) w - GuruFocus
Ligand Pharma a new Outperform at Barclays on biopharma royalty aggregation - TradingView
Barclays initiates Ligand Pharma stock with overweight rating - Investing.com
Barclays Initiates Ligand Pharmaceuticals at Overweight With $345 Price Target - Yahoo Finance
US53220KAJ7 Bond Profile: Coupon and Redemption - TradingView
Ligand Pharmaceuticals Invests Up to $47 Million in AvenCell - Yahoo Finance
Ligand and AvenCell Therapeutics Enter Financing Agreement - GlobeNewswire
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo Finance
McDermott Will & Schulte advises Ligand Pharmaceuticals in $23 million acquisition of royalty and milestone interest in Santen’s Ryjunea® - McDermott Will & Schulte
Ligand Pharmaceuticals Acquires Ryjunea Royalty Interest for $23 Million - Yahoo Finance
Sydnexis Announces Royalty Agreement with Ligand for Ryjunea® - Yahoo Finance
Ligand Pharmaceuticals: The Multiple Is The Whole Bet; Hold - Seeking Alpha
A Ligand (NASDAQ: LGND) director is planning a stock sale; the filing shows how big - Stock Titan
Ligand Pharmaceuticals CLO Reardon sells $1.43m in stock By Investing.com - Investing.com Australia
Ligand Pharmaceuticals CLO Reardon sells $1.43m in stock By Investing.com - Investing.com Nigeria
Ligand Pharmaceuticals CLO Reardon sells $1.43m in stock By Investing.com - Investing.com Australia
Ligand Pharmaceuticals CLO Reardon sells $1.43m in stock By Investing.com - Investing.com Canada
Ligand Pharmaceuticals (LGND) Rides Royalty Growth Hopes, Is The Stock Still Undervalued? - simplywall.st
Ligand Pharmaceuticals CLO Reardon sells $1.43m in stock By Investing.com - Investing.com South Africa
Ligand Pharmaceuticals CLO Reardon sells $1.43m in stock By Investing.com - Investing.com UK
Ligand Pharmaceuticals Incorporated (LGND) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
ETFs Investing in Ligand Pharmaceuticals Incorporated Stocks - TradingView
Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty Book - Yahoo Finance
Ligand (NASDAQ: LGND) insider to sell 15,000 shares after plan trades - Stock Titan
XOMA Royalty Reports $41.2M First-Half Net Loss on Trial Failures - Minichart
If You Invested $100 In Ligand Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today - Benzinga
A cash-heavy royalty arm at Ligand (NASDAQ: LGND) is loss-making - Stock Titan
Price to earnings forward of Ligand Pharmaceuticals Incorporated – OTC:LGNXZ - TradingView
Enterprise value to EBITDA forward of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView
Ligand Pharmaceuticals at Midwest IDEAS: royalty model gains scale By Investing.com - Investing.com Canada
Ligand to Participate in September Investor Conferences - marketscreener.com
Ligand executives will meet investors at three September events - Stock Titan
Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital - Yahoo Finance
Ligand (LGND) Snapshot: Ends Down by 2.13% at $280.18 for the Current Session; Price Setup: the Supplied Trading Band Runs From $266.17 to $294.19 at the CloseEarnings Breakout Stocks - vinanet.vn
Ligand Pharmaceuticals Inc Stock (LGND) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ligand Pharmaceuticals Inc Stock (LGND) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Reardon Andrew | CLO & Secretary |
Oct 02 '26 |
Sale |
304.07 |
5,000 |
1,520,346 |
31,854 |
| Zimmermann Martine | Director |
Sep 10 '26 |
Sale |
285.00 |
1,200 |
342,000 |
3,897 |
| MARTINE ZIMMERMANN | Director |
Sep 10 '26 |
Proposed Sale |
285.00 |
1,200 |
342,000 |
0 |
| ANDREW REARDON | Officer |
Sep 03 '26 |
Proposed Sale |
286.92 |
15,000 |
4,303,800 |
0 |
| Reardon Andrew | CLO & Secretary |
Sep 03 '26 |
Sale |
286.09 |
5,000 |
1,430,434 |
36,514 |
| Haas Jason | Director |
Aug 12 '26 |
Sale |
292.81 |
7,138 |
2,090,062 |
3,981 |
| Haas Jason | Director |
Aug 12 '26 |
Option Exercise |
51.56 |
6,138 |
316,475 |
11,119 |
| Espinoza Octavio | Chief Financial Officer |
Aug 12 '26 |
Option Exercise |
56.91 |
31,641 |
1,800,574 |
59,337 |
| OCTAVIO ESPINOZA | Officer |
Aug 12 '26 |
Proposed Sale |
288.75 |
31,641 |
9,136,339 |
0 |
| Jason Haas | Director |
Aug 12 '26 |
Proposed Sale |
292.81 |
7,138 |
2,090,062 |
0 |
1.95%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):